Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 653 trials

Retinitis Pigmentosa: Stem Cell Eye Treatment

We are testing a new stem cell-based treatment for people with retinitis pigmentosa to see if it is safe and tolerable. The study also aims to evaluate its potential to improve vision.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Advanced Solid Tumors: GSK5764227 Study

We are testing a new drug, GSK5764227, in people with advanced solid tumors to see how safe it is and how it affects their condition. This study aims to gather important information for future treatments.

Neoplasms1-2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: Anti-GD2 ADC M3554

We are testing a new treatment for patients with advanced solid tumors to see if it can improve their condition. This study aims to evaluate the safety and effectiveness of the drug.

Soft Tissue SarcomaGlioblastomaAdvanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Postoperative Pain Relief: PENG Block for Hip Surgery

We are studying whether a nerve block can reduce pain after hip surgery called peri-acetabular osteotomy. This trial compares the nerve block to a placebo to see if it helps patients feel better and use fewer pain medications.

Periacetabular Osteotomy1-2 yearsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyOtolaryngology

Advanced Solid Tumors: Saruparib Study

We are investigating how the drug saruparib works and its safety in adults with advanced solid tumors. This trial aims to provide insights into its potential benefits for patients.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Heart Attack Recovery: Bempedoic Acid Study

We are investigating whether adding bempedoic acid to standard cholesterol medications helps heart attack patients reach their cholesterol goals. This study aims to improve treatment for those not meeting guidelines with current therapies.

Heart Attack1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Vibegron for Children with Neurogenic Detrusor Overactivity

We are studying the safety and effectiveness of vibegron in children aged 2 to under 18 with neurogenic detrusor overactivity who use clean intermittent catheterization. This trial aims to understand how well the medication works and how it is processed in young patients.

Neurogenic Bladder1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsUrology

Ovarian Stimulation: Follitropin Delta and Dydrogesterone

We are studying a new ovarian stimulation method for egg donors to see if it produces similar results to traditional approaches. This research may help improve fertility treatments in the future.

Healthy Oocyte Donors1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Osteoarthritis of the Knee: SAR446959 Study

We are investigating a new treatment to see if it is safe and well-tolerated by people with knee osteoarthritis. This study aims to gather important information about its effects on participants.

Osteoarthritis1-2 yearsSafety phase (I)Internal MedicineOrthopedics and Traumatology

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Lung Cancer Treatment: CT-P51 vs. Keytruda

We are comparing the effects and safety of CT-P51 and Keytruda in patients with untreated metastatic lung cancer. This study aims to find out if CT-P51 works as well as Keytruda when combined with chemotherapy.

Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Chronic Lymphocytic Leukemia: Lisaftoclax and Acalabrutinib Study

We are testing a new drug combination for patients newly diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The study aims to see if this combination improves survival without disease progression compared to standard treatments.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Intracerebral Hemorrhage: Anticoagulation Strategies

We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.

Cerebral Hemorrhage1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Ginisortamab for Advanced Pancreatic Cancer

We are studying the safety and effectiveness of ginisortamab combined with standard treatments for metastatic pancreatic cancer. This trial will help us understand how well it works and its potential side effects.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesGastroenterologyOncology

Systemic Lupus Erythematosus: GSK4527363 Study

We are investigating a new treatment for systemic lupus erythematosus in healthy individuals and those with the condition. The study includes participants from Chinese and Japanese backgrounds to see how the treatment works across different groups.

Systemic Lupus Erythematosus1-2 yearsSafety phase (I)Rheumatology

Navepegritide for Growth in Adolescents with Achondroplasia

We are studying whether navepegritide can help improve growth in adolescents aged 12 to under 18 with achondroplasia. This trial will help us understand its effectiveness and safety.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Spinal Muscular Atrophy: Nusinersen via ThecaFlex DRx System

We are studying how the body processes nusinersen when given through the ThecaFlex DRx system in adults and children with spinal muscular atrophy. This research aims to compare it to the standard delivery method.

Spinal Muscular Atrophy1-2 yearsSafety phase (I)No PlaceboStandard MedicinesHematologyInternal MedicineNeurology

Esophageal Cancer: Ifinatamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for people with untreated advanced esophageal cancer. The goal is to see if it is safe and effective compared to standard options.

Esophageal Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesOncology

Oxygen Supply After Non-Cardiac Surgery: AIOLOS Trial

We are studying whether providing extra oxygen helps patients maintain better oxygen levels and improves recovery after non-cardiac surgery. This trial compares supplemental oxygen to standard care in the first days post-surgery.

Postoperative Complications Risk after General SurgeryPostoperative Complications Risk after Urology Surgery1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePulmonology

Primary Sclerosing Cholangitis: Norucholic Acid Tablets

We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.

Primary Sclerosing Cholangitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatology